Select Publications
Journal articles
2024, 'Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-082553
,2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390
,2024, 'Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention', International Journal of Drug Policy, 126, http://dx.doi.org/10.1016/j.drugpo.2024.104383
,2024, 'Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study', European Addiction Research, 30, pp. 121 - 125, http://dx.doi.org/10.1159/000536328
,2024, 'Provider costs of treating opioid dependence with extended-release buprenorphine in Australia', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13956
,2023, 'Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review', Psychopharmacology, 240, pp. 127 - 135, http://dx.doi.org/10.1007/s00213-022-06283-6
,2023, 'Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series', Drug and Alcohol Review, 42, pp. 27 - 32, http://dx.doi.org/10.1111/dar.13556
,2022, 'Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial', Drug and Alcohol Dependence, 241, pp. 109692, http://dx.doi.org/10.1016/j.drugalcdep.2022.109692
,2022, 'Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal', PLoS ONE, 17, pp. e0275371, http://dx.doi.org/10.1371/journal.pone.0275371
,2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100, http://dx.doi.org/10.1016/j.drugpo.2021.103492
,2022, 'What do General Practitioners want from Specialist Alcohol and Other Drugs Services? A Qualitative Study of NSW Metropolitan GPs', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13463
,2018, 'Brief interventions for alcohol and other drug use', Australian Prescriber, 41, pp. 117 - 121, http://dx.doi.org/10.18773/AUSTPRESCR.2018.031
,2018, 'Substance Use and Sex Index (SUSI): First stage development of an assessment tool to measure behaviour change in sexualised drug use for substance use treatment studies', International Journal of Drug Policy, 55, pp. 165 - 168, http://dx.doi.org/10.1016/j.drugpo.2018.03.020
,2018, 'An anxious man with codeine dependence: Opioid maintenance therapy', Medicine Today, 19, pp. 35 - 36
,2016, 'Diagnosis-based emergency department alcohol harm surveillance: What can it tell us about acute alcohol harms at the population level?', Drug and Alcohol Review, pp. n/a - n/a, http://dx.doi.org/10.1111/dar.12458
,2013, 'What proportion of sexually transmissible infections and HIV are diagnosed in New South Wales public sexual health services compared with other services? (vol 10, pg 119, 2013)', SEXUAL HEALTH, 10, pp. 290 - +, http://dx.doi.org/10.1071/SH12020_CO
,2013, 'A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia', Preventive Medicine, Advance online publication, pp. 1 - 7, http://dx.doi.org/10.1016/j.ypmed.2013.04.013
,2013, 'What proportion of sexually transmissible infections and HIV are diagnosed in New South Wales? public sexual health services compared with other services?', Sexual Health, 10, pp. 119 - 119, http://dx.doi.org/10.1071/SH12020
,2011, 'A RANDOMISED CONTROLLED TRIAL OF CONTINGENCY MANAGEMENT TO INCREASE HEPATITIS B VACCINATION UPTAKE AND COMPLETION AMONG PEOPLE WHO INJECT DRUGS IN AUSTRALIA', DRUG AND ALCOHOL REVIEW, 30, pp. 86 - 87, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297019700266&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence', Drug and Alcohol Review, 29, pp. 235 - 242, http://dx.doi.org/10.1111/j.1465-3362.2009.00148.x
,2010, 'Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status', Drug and Alcohol Dependence, 108, pp. 134 - 137, http://dx.doi.org/10.1016/j.drugalcdep.2009.11.013
,2009, 'A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence', Addiction, 104, pp. 224 - 233, http://dx.doi.org/10.1111/j.1360-0443.2008.02437.x
,2008, 'Sexually transmissible infection testing guidelines for men who have sex with men', Sexual Health, 5, pp. 189 - 191
,Conference Papers
2022, 'Can e-cigarettes assist opiate agonist treatment clients to quit smoking? Preliminary results from HARMONY, a multi-site, single-blinded randomised controlled trial of e-cigarettes and nicotine replacement therapy', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S26 - S27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700047&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Abstracts
2022, 'An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S23 - S24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Reports
2023, Considerations for delivering extended-release buprenorphine for opioid dependence in Australia: Preliminary lessons from the Community Long-Acting Buprenorphine (CoLAB) trial, NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2020, RANDWICK, 355, http://dx.doi.org/10.26190/zemp-dx93
,